Patients with metastatic breast cancer previously treated with anthracyclines for advanced disease are usually refractory to any further treatment with anthracyclines and have a poor prognosis. Therefore, new drugs or new combinations of drugs are needed. One approach has been to focus on the type of chemotherapy with low toxicity that preserves quality of life during treatment, such as weekly drug administration.
Study design
We designed a dose-finding study to determine the maximum tolerated dose of gemcitabine plus docetaxel, given on a weekly schedule in metastatic breast cancer previously treated with anthracyclines. Three escalating doses of gemcitabine (900, 1000 and 1100 mg/m2) on days 1 and 8 in combination with a fixed dose of docetaxel, 35 mg/m2 on days 1 and 8 were planned. Dose-limiting toxicity included grade >3 hematologic toxicity, grade >2 stomatitis, asthenia, diarrhea or organ-specific toxicity (except alopecia). Dose escalation was stopped if 1 out of 3 patients at any dose level experienced dose-limiting toxicity.
Results
Nine patients received a mean of 5.1 (range, 1–9) cycles. Gastrointestinal and leukopenia were the main dose-limiting toxicity. No patient experienced dose-limiting toxicity at dose level 1; at dose level 2, 2 out of 3 patients had dose-limiting toxicity and 3 additional patients treated at dose level 2 confirmed that the maximum tolerated dose had been reached.
Conclusions
The recommended gemcitabine dose in combination with docetaxel (35 mg/m2 for a phase II study) was established at 900 mg/m2.
HonigS.F.: Treatment of metastatic disease: Hormonal and chemotherapy. In: Diseases of the Breast, HarrisJ.R., LippmanM.E., MorrowM., HellmanS. (Eds), pp 669–734, Lippincott-Raven, Philadelphia, 1996.
2.
MussH.B., CaseL.D., RichardsF., WhiteD.R., CooperM.R., CruzJ.M., PowellB.L., SpurrC.L., CapizziR.L.: Interrupted vs continuous chemotherapy in patients with metastatic breast cancer. N Eng J Med, 325: 1342–1348, 1991.
3.
BuzdarA.V., LeghaS., HortobagyiG., YapH.Y., WisemanC.L., DistefanoA., SchellF.C., BarnesB.C., CamposL.T., BlumenscheinG.R.: Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer, 47: 2798–2802, 1981.
4.
PiccartM.J., AwadaA.: State of the art chemotherapy for advanced breast cancer. Semin Oncol, 27(Suppl 9): 3–12, 2000.
5.
AndersonH., LundB., BachF., ThatcherN., WallingJ., HansenH.H.: Single agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol, 12: 1821–1826, 1994.
6.
CarmichaelJ., FinkU., RussellR.C., SpittleM.F., HarrisA.L., SpiessiG., BlatterJ.: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer, 73: 101–105, 1996.
7.
Ulrich-PurH., KornekG.V., RadererM., HaiderK., KwasnyW., DepischD., GreulR., SchneeweissB., KraussG., FunovicsJ., ScheithauerW.: A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic carcinoma. Cancer, 88: 2505–2511, 2000.
8.
LundB., HansenO.P., TheiladeK., HansenM.: Phase II study of gemcitabine (2′-2′-difluorodeoxycytidine) in previously treated ovarian cancer. J Natl Cancer Inst, 86: 1530–1533, 1994.
9.
BlacksteinM., VogelC.L., AmbinderR., CowanJ., PearceG.: Phase II study of gemcitabine in patients with metastatic breast cancer. Eur J Cancer, 33: S149, 1997.
10.
CarmichaelJ., PossingerK., PhilipP., BeykirchM., KerrH., WallingJ., HarrisA.L.: Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol, 13: 2731–2736, 1995.
11.
PossingerK., KaufmannM., ColemanR., StuartN.S., HelsingM., OhnmachtU., ArningM.: Phase II study of gemcitabine as first-line chemotherapy with advanced or metastatic breast cancer. Anti-Cancer Drugs, 10: 155–162, 1999.
12.
GersonR., SenaroA., VillabbosA., OrtizC., Sanchez-ForgachE.: Gemcitabine response in advanced breast cancer in relation to immunohistochemical factors. Proc Am Clin Oncol, 19(abstr 572), 2000.
13.
ValerioM., CiceroG., ArmataM., BajardiE., CrostaA., BadalamentiG., ArcaraC., AgostaG., VieniS., LatteriF., RussoA., GulottaG., GebbiaN.: Gemcitabibe in pretreated breast cancer. Proc Am Clin Oncol, 20(abstr 1953), 2001.
14.
BrodowiczT., KoestlerW.J., TomekS., VaclavikI., HerscoviciV., WiltschkeC., StegerG.G., WeinW., SeifertM., KubistaE., ZielinskiC.C.: Single agent gemcitabine as second and third line treatment in metastatic breast cancer. Anti Cancer Drugs, 11: 149–153, 2000.
15.
SpielmannM., KallaS., Llombart-CussacA., EspieM., NamerM., FerreroJ.M., CuvierC., FumoleauP., PonzioA., KayitalireL., PouillartP.: Activity of gemcitabine in metastatic breast cancer (MBC) patients previously treated with anthracycline-containing regimens. Eur J Cancer, 33: S149, 1997.
16.
FountzilasG., NicolaidesC., BafaloukosD., Kalogera FountzilaA., KalofonosH., SamelisG., AravantinosG., PavlidisN.: Docetaxel and gemcitabinein anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group phase II study. Cancer Invest, 18: 503–509, 2000.
17.
LenzF., SchneeweissA., BeldermannF., MatthiasG., GuntherB.: A phase II study of first line combination chemotherapy with docetaxel (D) and gemcitabine (G) in anthracycline-pretreated, Her2 negative, metastatic breast cancer. Ann Oncol, 13(Suppl 5) 53 (abstr 168P), 2002.
18.
LaufmanL.R., SpiridonidisC.H., PritchardJ., RoachR., ZangmeisterJ., LarrimerN., MooreT., SegalM., JonesJ., PatelT., GuttermanL., CarmanL., ColbornD., KueblerJ.P.: Monthly docetaxel and weekly gemcitabine in metastatic breast caner: a phase II study. Ann Oncol, 12: 1259–1264, 2001.
19.
MavroudisD., MalamosN., AlexopoulosA., KourousisC., AgelakiS., SarraE., PotamianouA., KosmasC., RigatosG., GiannakakisT., KalbakisK., ApostolakiF., VlachonicolisJ., KakolyrisS., SamonisG., GeorgouliasV.: Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek breast cancer cooperative group. Ann Oncol, 10: 211–215, 1999.
20.
AlexopoulosA., TryfonopoulosD., KaramouizisM.V., GerasimidisG., KarydasI., KandilisK., StavrakakisJ., StavrakakisJ., StavrinidesH., GeorgantaC., ArdavanisA., RigatosG.: Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Ann Oncol, 15: 95–99, 2004.
21.
BrandiM., GiottaF., ViciP., ValerioM.R., VinciarelliG., GebbiaV., GalettaD., LopezM., ColucciG.: Salvage chemotherapy with docetaxel (TXT) and gemcitabine (GEM) in metastatic breast cancer (MBC): preliminary results of a multicenter phase II trial of GOIM. Proc ASCO, 20–52b (abst 1956), 2001.
22.
KaracetinD., MaralO., AksakalO., OktenB., YalcinB., IncekaraO.: Gemcitabine and docetaxel combination regimen in metastatic breast cancer (MBC). Proc ASCO, 2518S, (abstr 1107), 2007.
23.
Del MastroL., VenturiniM., LionettoR., CarninoF., GuarneriD., GalloL., ContuA., PronzatoP., VesentiniL., BersaglioM., ComisS., RossoR.: Accelerated-intensified cyclophosphamide, epirubicin and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of Italian Gruppo Oncologico Nord-Ovest Mammella Inter Gruppo Group. J Clin Oncol, 19: 2213–2221, 2001.
24.
FossatiR., ConfalonieriC., TorriV., GhislandiE., PennaA., PistottiV., TinazziA., LiberatiA.: Cytotoxic and hormonal treatment for metastatic breast cancer: a systemic review of published randomized trials involving 31,510 women. J Clin Oncol, 16: 3439–3460, 1998.
25.
SledgeG.W., NeubergD., BernardoP., IngleJ., MartinoS., RowinskyE.K., WoodW.C.: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol, 15: 588–592, 2003.
26.
ValeroV., HolmesF.A., WaltersR.S., TheriaultR.L., EsparzaL., FraschiniG., FonsecaG.A., BelletR.E., BuzdarA.U., HortobagyiG.N.: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol, 13: 2886–2894, 1995.
27.
RavdinP.M., BurrisHAIII, CookG., EisembergP., KaneM., BiermanW.A., MortimerJ., GenevoisE., BelletR.E.: Phase II trial of docetaxel in advanced anthracycline-resistant or antracenedione-resistant breast cancer. J Clin Oncol, 13: 2879–2885, 1995.
28.
LofflerT.M.: Is there a place for “dose-dense” weekly schedules of the taxoids?Semin Oncol, 25 (suppl 12): 32–34, 1998.
29.
HainsworthJ.D., BurrisH.A., ErlandJ.B., ThomasM., GrecoF.A.: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol, 16: 2164–2168, 1998.
30.
TaberneroJ., ClimentM.A., LluchA., AlbanelliJ., VermokenJ.B., BamadasT., MayordomoJ.I., EstaunN., LosaI., GuillemV., Garcia CondeJ., TisaireJl: A multicentre, randomised study of weekly or 3 weekly docetaxel in patients with metastatic breast cancer. Ann Oncol, 15: 1358–1365, 2004.
31.
BrugnatelliS., DanovaM., Tamburo de BellaM., VaglicaM., ManuguerraG., RiccardiA., PalmeriS.: Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study. Oncology, 62: 33–38, 2002.
32.
PalmeriS., VaglicaM., SpadaS., FilippelliG., FarrisA., PalmeriL., MassiddaB., MisinoA., FerraùF., ComellaG., LeonardiV., CondemiG., MangiameliA., De CataldisG., MacalusoM.C., CajozzoM., IannittoE., DanovaM.: Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study. Oncology, 68: 438–445, 2005.
